Skip to main content
Akeso, Inc. logo

Akeso, Inc. — Investor Relations & Filings

Ticker · 9926 ISIN · KYG0146B1032 LEI · 254900ECWYGR3QW5GF30 HKEX Manufacturing
Open in API
Filings indexed 334 across all filing types
Latest filing 2025-06-08 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 9926

About Akeso, Inc.

http://www.akesobio.com

Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 2025
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a form of proxy for shareholders to appoint proxies and vote at the company’s upcoming Annual General Meeting, providing resolution details and voting instructions. This is part of the materials sent to shareholders to solicit their votes rather than the meeting presentation itself. It therefore falls under Proxy Solicitation & Information Statement (PSI).
2025-06-08 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the company’s Annual General Meeting including proposed resolutions, proxy appointment instructions, and voting details. It is sent to shareholders to provide information ahead of the meeting and solicit proxies. This matches the definition of Proxy Solicitation & Information Statement (PSI).
2025-06-08 English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; PROPOSED RE-APPOINTMENT OF AUDITORS&#x3b; AND NOTICE OF ANNUAL GENERA
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular containing the notice of the Annual General Meeting, explanatory letter from the board, proposed resolutions (granting general mandates, re-election of directors, re-appointment of auditors) and proxy instructions. It is not the AGM presentation itself, nor is it a financial report, earnings release, or regulatory announcement. This matches the definition of a Proxy Solicitation & Information Statement (PSI) – materials sent to shareholders to provide information about meeting agenda items and request voting. Therefore the correct classification is PSI.
2025-06-08 English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement filed on the Hong Kong Exchange regarding the approval of a supplemental New Drug Application (sNDA) by the China NMPA for the company’s drug. It does not present financial results, quarterly or annual reports, nor does it announce share issues, dividends, management changes, or meeting materials. It is a general regulatory announcement to shareholders and investors. Therefore it falls under the fallback category of Regulatory Filings (RNS).
2025-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2025
Regulatory Filings Classification · 1% confidence The document is a standard HKEX Form FF301 “Monthly Return for Equity Issuer… on Movements in Securities” covering share capital, issued shares, share options and other equity movements for the month ended 31 May 2025. It is a periodic regulatory submission required under the Hong Kong Listing Rules rather than an annual or interim financial report, earnings release, investor presentation or a one-off event announcement. It does not announce specific new financing (CAP), share issues (SHA), buybacks (POS), or director dealings (DIRS), nor is it a proxy statement, governance code, ESG report, etc. As it is a routine regulatory filing for share movements with no direct counterpart in the predefined categories, it falls under the fallback category “Regulatory Filings (RNS).”
2025-06-04 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Director's Dealing Classification · 1% confidence The document is an announcement under Hong Kong Listing Rules detailing the grant of share options and restricted share units to directors and employees. It reports insider-related share transactions (grant of equity awards) rather than a full financial report or dividend notice. This aligns with the definition of Director’s Dealing (insider share transactions including option grants).
2025-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.